GAROFALO HEALTH CARE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.1 EUR | -.--% |
|
+0.79% | +9.91% |
| May. 15 | Garofalo Health Care in the quarter increases profit and revenues | AN |
| May. 15 | Garofalo Health Care S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2024 * | 463M 502M | Sales 2025 * | 472M 512M | Capitalization | 451M 490M |
|---|---|---|---|---|---|
| Net income 2024 * | 26M 28.2M | Net income 2025 * | 28M 30.37M | EV / Sales 2024 * | 1.36 x |
| Net Debt 2024 * | 178M 193M | Net Debt 2025 * | 140M 152M | EV / Sales 2025 * | 1.25 x |
| P/E ratio 2024 * |
17.3
x | P/E ratio 2025 * |
16.5
x | Employees | 2,767 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 35.28% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 week | +0.79% | ||
| 1 month | +8.28% | ||
| 3 months | +6.25% | ||
| 6 months | +13.33% | ||
| Current year | +9.91% |
1 week
5.04
5.18
1 month
4.755.18
Current year
4.375.20
1 year
3.925.20
3 years
3.586.10
5 years
3.586.32
10 years
3.506.32
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 00-04-19 | |
Luigi Celentano
DFI | Director of Finance/CFO | - | 21-04-30 |
| Chief Administrative Officer | - | 21-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 56 | 18-08-07 | |
| Director/Board Member | 52 | - | |
| Director/Board Member | 55 | 20-04-28 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 5.1 | -.--% | 2,980 |
| 24-05-30 | 5.1 | -.--% | 3,658 |
| 24-05-29 | 5.1 | -0.78% | 12,720 |
| 24-05-28 | 5.14 | +1.58% | 46,531 |
| 24-05-27 | 5.06 | -.--% | 7,912 |
Real-time Borsa Italiana, May 31, 2024 at 11:44 am EDT
More quotes
Garofalo Health Care SpA is an Italy-based healthcare group. The Group manages facilities across northern and central Italy, both private and accredited, providing a wide range of services and specializations covering all sectors of the health and social care sectors, among others, medicine, surgery, cardiology, rehabilitation, extended and intensive care units, psychiatric and diagnostic centers. Additionally, the Company is active in the research field in collaboration with Italian and foreign research institutions and universities.
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.1
EUR
Average target price
6.5
EUR
Spread / Average Target
+27.45%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +9.91% | 490M | |
| -23.39% | 15.56B | |
| -2.70% | 11.65B | |
| +2.65% | 11.58B | |
| +2.37% | 10.06B | |
| +29.48% | 8.7B | |
| -10.45% | 7.16B | |
| +8.05% | 6.85B | |
| +3.94% | 5.71B | |
| +13.33% | 4.3B |
- Stock Market
- Equities
- GHC Stock
